Literature DB >> 10910951

Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells.

M H Wang1, A L Kurtz, Y Chen.   

Abstract

The RON receptor tyrosine kinase is a 180 kDa heterodimeric protein composed of a 40 kDa alpha chain and a 145 kDa beta chain with intrinsic tyrosine kinase activity. Activation of RON causes cell dissociation, motility and invasion of extracellular matrices, suggesting that RON might be involved in tumor metastasis. We report here the cloning of a novel splice variant of RON in human colorectal carcinoma cell line HT-29. This RON variant is first produced as a single chain precursor with a molecular mass of 160 kDa. Proteolytic cleavage results in a 40 kDa alpha chain and a short form of the beta chain with a molecular mass of 125 kDa. The altered receptor is synthesized from a transcript differing from the full-length RON mRNA by an in-frame deletion of 109 amino acids in the extracellular domain of the RON beta chain. The consequence of the deletion is constitutive activation of the protein with autophosphorylation. Expression of the RON variant in colon epithelial CoTr cells results in increased cell migration and invasion of extracellular matrices. These data suggest that generation of the activated splice variant of RON may contribute to the invasive phenotype of human colorectal carcinomas in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910951

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  26 in total

1.  MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma.

Authors:  Young Wha Koh; Yang-Soon Park; Hyo Jeong Kang; Ju Hyun Shim; Eunsil Yu
Journal:  Tumour Biol       Date:  2015-02-10

2.  Effects of PTCs on nonsense-mediated mRNA decay are dependent on PTC location.

Authors:  Heegyum Moon; Xuexiu Zheng; Tiing Jen Loh; Ha Na Jang; Yongchao Liu; Da-Woon Jung; Darren R Williams; Haihong Shen
Journal:  Oncol Lett       Date:  2017-01-19       Impact factor: 2.967

Review 3.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

4.  A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.

Authors:  Dai Hoon Han; Chang Moo Kang; Sung Whan Lee; Ho Kyoung Hwang; Woo Jung Lee
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

Review 5.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

6.  Prognostic significance of phosphorylated RON in esophageal squamous cell carcinoma.

Authors:  Marco K C Hui; Kenneth K Y Lai; Kwok Wah Chan; John M Luk; Nikki P Lee; Yvonne Chung; Leo C Cheung; Gopesh Srivastava; Sai Wah Tsao; Johnny C Tang; Simon Law
Journal:  Med Oncol       Date:  2011-11-16       Impact factor: 3.064

7.  Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.

Authors:  Young Wha Koh; Dok Hyun Yoon; Cheolwon Suh; Hee Jeong Cha; Jooryung Huh
Journal:  Int J Exp Pathol       Date:  2015-04-27       Impact factor: 1.925

Review 8.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 9.  The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Authors:  Chang Moo Kang; Michele L Babicky; Andrew M Lowy
Journal:  Pancreas       Date:  2014-03       Impact factor: 3.327

10.  Recepteur d'Origine nantais (RON) tyrosine kinase splicing variants lacking exons 18 and 19 occur ubiquitously in lung cancer.

Authors:  Soundararajan Krishnaswamy; Abdul Khader Mohammed; Osama E Amer; Gyanendra Tripathi; Majed S Alokail; Nasser M Al-Daghri
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.